skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation

Abstract

Purpose: Triple negative receptor status (TNRS) of patients undergoing breast-conserving therapy treated with whole-breast irradiation has been associated with increased distant metastasis and decreased disease-free and overall survival. This paper reports the outcomes of TNRS patients treated with accelerated partial breast irradiation (APBI). Methods and Materials: We studied 455 patients who received APBI at our institution, using interstitial, intracavitary, and three-dimensional conformal radiation therapy. TNRS was assigned if a patient tested negative for all three (ER [estrogen receptor], PR [progesterone receptor], and HER2/neu) receptors. Of 202 patients with all receptor results available, 20 patients were designated TNRS, and 182 patients had at least one receptor positive (RP). We analyzed ipsilateral breast tumor recurrence (IBTR), regional nodal failure (RNF), distant metastasis (DM), and overall survival (OS). Results: Mean follow-up was 4.1 years for the TNRS group and 5.1 years for the RP cohort (p = 0.11). TNRS patients had a higher histologic grade (59% TNRS vs. 13% RP; p < 0.001). Mean tumor size, stage N1 disease, and margin status were similar. Based on a 5-year actuarial analysis, the TNRS cohort experienced no IBTR, RNF, or DM, with an OS of 100% versus rates of 1.4% IBTR, 1.5% RNF, and 2.8%more » DM in the RP cohort (p > 0.52). OS for the RP cohort was 93% at 5 years (p > 0.28). Conclusions: In our patient population, TNRS conferred a clinical outcome similar to that of patients with RP disease treated with APBI. Further investigation with larger patient populations and longer follow-up periods is warranted to confirm that APBI is a safe and effective treatment for patients with localized TNRS breast cancer.« less

Authors:
 [1];  [2]; ; ; ; ; ;  [1];  [2]
  1. Department of Radiation Oncology, William Beaumont Hospital, Beaumont Cancer Institute, Royal Oak, Michigan (United States)
  2. Department of Hematology and Oncology, William Beaumont Hospital, Beaumont Cancer Institute, Oakland University William Beaumont Hospital School of Medicine, Royal Oak, Michigan (United States)
Publication Date:
OSTI Identifier:
21590458
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 81; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2010.12.031; PII: S0360-3016(11)00019-8; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ESTROGENS; FAILURES; IRRADIATION; MAMMARY GLANDS; METASTASES; NEOPLASMS; PROGESTERONE; RADIOTHERAPY; RECEPTORS; BODY; DISEASES; GLANDS; HORMONES; KETONES; MEDICINE; MEMBRANE PROTEINS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; PREGNANES; PROTEINS; RADIOLOGY; STEROID HORMONES; STEROIDS; THERAPY

Citation Formats

Wilkinson, J Ben, Reid, Robert E, Shaitelman, Simona F, Chen, Peter Y, Mitchell, Christine K, Wallace, Michelle F, Marvin, Kimberly S, Grills, Inga S, Margolis, Jeffrey M, and Vicini, Frank A., E-mail: fvicini@beaumont.edu. Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.12.031.
Wilkinson, J Ben, Reid, Robert E, Shaitelman, Simona F, Chen, Peter Y, Mitchell, Christine K, Wallace, Michelle F, Marvin, Kimberly S, Grills, Inga S, Margolis, Jeffrey M, & Vicini, Frank A., E-mail: fvicini@beaumont.edu. Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation. United States. https://doi.org/10.1016/j.ijrobp.2010.12.031
Wilkinson, J Ben, Reid, Robert E, Shaitelman, Simona F, Chen, Peter Y, Mitchell, Christine K, Wallace, Michelle F, Marvin, Kimberly S, Grills, Inga S, Margolis, Jeffrey M, and Vicini, Frank A., E-mail: fvicini@beaumont.edu. 2011. "Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation". United States. https://doi.org/10.1016/j.ijrobp.2010.12.031.
@article{osti_21590458,
title = {Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation},
author = {Wilkinson, J Ben and Reid, Robert E and Shaitelman, Simona F and Chen, Peter Y and Mitchell, Christine K and Wallace, Michelle F and Marvin, Kimberly S and Grills, Inga S and Margolis, Jeffrey M and Vicini, Frank A., E-mail: fvicini@beaumont.edu},
abstractNote = {Purpose: Triple negative receptor status (TNRS) of patients undergoing breast-conserving therapy treated with whole-breast irradiation has been associated with increased distant metastasis and decreased disease-free and overall survival. This paper reports the outcomes of TNRS patients treated with accelerated partial breast irradiation (APBI). Methods and Materials: We studied 455 patients who received APBI at our institution, using interstitial, intracavitary, and three-dimensional conformal radiation therapy. TNRS was assigned if a patient tested negative for all three (ER [estrogen receptor], PR [progesterone receptor], and HER2/neu) receptors. Of 202 patients with all receptor results available, 20 patients were designated TNRS, and 182 patients had at least one receptor positive (RP). We analyzed ipsilateral breast tumor recurrence (IBTR), regional nodal failure (RNF), distant metastasis (DM), and overall survival (OS). Results: Mean follow-up was 4.1 years for the TNRS group and 5.1 years for the RP cohort (p = 0.11). TNRS patients had a higher histologic grade (59% TNRS vs. 13% RP; p < 0.001). Mean tumor size, stage N1 disease, and margin status were similar. Based on a 5-year actuarial analysis, the TNRS cohort experienced no IBTR, RNF, or DM, with an OS of 100% versus rates of 1.4% IBTR, 1.5% RNF, and 2.8% DM in the RP cohort (p > 0.52). OS for the RP cohort was 93% at 5 years (p > 0.28). Conclusions: In our patient population, TNRS conferred a clinical outcome similar to that of patients with RP disease treated with APBI. Further investigation with larger patient populations and longer follow-up periods is warranted to confirm that APBI is a safe and effective treatment for patients with localized TNRS breast cancer.},
doi = {10.1016/j.ijrobp.2010.12.031},
url = {https://www.osti.gov/biblio/21590458}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 81,
place = {United States},
year = {Tue Nov 01 00:00:00 EDT 2011},
month = {Tue Nov 01 00:00:00 EDT 2011}
}